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Background: Lung cancer is the leading cause of cancer-related deaths in the US. Recombinant vectors based on
adeno-associated virus (AAV) and lentivirus are promising delivery tools for gene therapy due to low toxicity and
long term expression. The efficiency of the gene delivery system is one of the most important factors directly
related to the success of gene therapy.
Methods: We infected SCLC cell lines, SHP-77, DMS 53, NCI-H82, NCI-H69, NCI-H727, NCI-H1155, and NSCLC cell
lines, NCI-H23, NCI-H661, and NCI-H460 with VSV-G pseudo-typed lentivirus or 5 AAV serotypes, AAV2/1, AAV2/2,
AAV2/4, AAV2/5, and AAV2/8 expressing the CMV promoter mCherry or green fluorescent protein transgene (EGFP).
The transduction efficiency was analyzed by fluorescent microscopy and flow cytometry.
Results: Of all the serotypes of AAV examined, AAV2/1 was the optimal serotype in most of the lung cancer cell
lines except for NCI-H69 and NCI-H82. The highest transduction rate achieved with AAV2/1 was between 30–50% at
MOI 100. Compared to all AAV serotypes, lentivirus had the highest transduction efficiency of over 50% at MOI 1.
Even in NCI-H69 cells resistant to all AAV serotypes, lentivirus had a 10-40% transduction rate. To date, AAV2 is the
most widely-used serotype to deliver a transgene. Our results showed the transduction efficiency of AAVs tested
was AAV2/1 > AA2/5 = AAV2/2> > AAV2/4 and AAV2/8.
Conclusions: This study demonstrated that VSV-G pseudotyped lentivirus and AAV2/1 can mediate expression of a
transgene for lung cancer gene therapy. Overall, our results showed that lentivirus is the best candidate to deliver a
transgene into lung cancer cells for treatment.
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Lung cancer remains the most common cause of cancer-
related death in USA and worldwide. In the United
States, the number of lung cancer deaths exceeds the
rates from breast, prostate, and colon cancers combined.
There are two main types of lung cancer, non-small cell
lung cancer (NSCLC) and small cell lung cancer (SCLC).
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reproduction in any medium, provided the orpropensity to metastasize and to be resistant to chemo-
therapy and radiation therapy [1,2]. Gene therapy provides
a new and promising treatment for those patients who
have both chemo- and radiotherapy resistant relapse. One
of the most important factors directly related to the suc-
cess of gene therapy is the efficiency of the gene delivery
system [3,4].
Adeno-associated virus, AAV, is emerging as one of
the most popular gene delivery systems because of a lack
of pathogenicity in humans, and its long term and efficient
transgene expression in various cells. At least 11 serotypes
of AAVs have been isolated from animal tissues and the
cell tropism is different among the serotypes [5-8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that lack the necessary cellular receptor components for
infection, the transduction efficiency is limited. High titers
of virus are required to achieve an effective level of trans-
gene expression. Many studies suggest that replacement
of the AAV2 capsid with the capsid from other AAV sero-
types results in increased cell tropism [9]. The transduc-
tion efficiency of AAVs in lung cancer cells has not been
extensively studied. One report showed that SCLC was
completely refractory to AAV2 transduction due to a
complete lack of the cell receptor on the cell surface [10].
Several studies indicated AAV1 and AAV5 were the opti-
mal serotypes for infection of lung epithelial cells [11-13].
Analysis of nine serotyopes of AAV in mice showed that
AAV4 resulted in the greatest number of genome copies
in lung [7]. In this study, we used the recombinant AAV2
(rAAV) backbone and replaced the capsid gene with the
AAV1, AAV4, AAV5, and AAV8 serotypes.
Lentiviral vectors have been proposed as an efficient
gene delivery system for gene therapy. The vectors can
achieve stable long term expression of the transgene and
high transduction efficiency in various cells and tissue
[14]. To increase the transduction efficiency and the
cellular tropism of lentivirus, the lentiviral envelope is
substituted by the vesticular stomatitis virus glycoprotein
(VSV-G) because its phospholipid receptor is widely
expressed in a variety of cells [15,16].
In this study, we compare the transduction efficiency
of 5 serotypes of rAAVs with a VSV-G pseudotyped
lentiviral vector expressing the fluorescent genes, mCherry
or EGFP in 11 different lung cancer cell lines (both
NSCLC and SCLC). Our results provide valuable informa-
tion for choosing an efficient delivery system for lung can-
cer gene therapy.
Results
Transduction efficiency of 5 serotypes rAAV vectors in
lung cancer cell lines
To compare the transduction efficiency of rAAV sero-
types in lung cancer cells, six lung cancer cell lines,
DMS 53, NCI-H460, SHP-77, NCI-H82, NCI-H1155 and
NCI-H69 were infected with MOI 100 AAV2/1, AAV2/2,
AAV2/4, AAV2/5 and AAV2/8 that carried the CMV
promoter–driven mCherry transgene. On day 6 post-in-
fection, mCherry expression was detected by fluorescent
microscopy and FACS analysis. Seventy-two hours post-
infection, a weak fluorescent signal was observed in the
tranduced cells, SHP-77, NCI-H1155, NCI-H460 and
DMS 53. The percentage of mCherry positive cells in-
creased in a time-dependent manner (data not show).
The results indicate that the lung cancer cells tested were
highly resistant to AAV2/4 and AAV2/8 infection.
Only DMS 53 cells, NCI-H23 and NCI-H661 were
infected by the AAV2/4 and the AAV2/8 virus howeverthe transduction rate was low (13%–6%) (Figure 1B, 1D,
Table 1). Only a few SHP-77 and NCI-H1155 cells were
infected by the AAV2/8 virus but the proportion was very
low, only 5.1% and 3.3%. The NCI-H82 and NCI-H69 cell
lines were completely refractory to all AAV serotypes
tested (Figure 1B). The highest transduction efficiency
achieved was with the NCI-H460 cells with AAV2/1,
AAV2/2 and AAV2/5 and reached around 40% (Figure 1B,
Table 1). Given the observation that AAV2/1, AAV2/2 and
AAV2/5 gave the most promising transduction rates in
NCI-H460, DMS 53, SHP-77 and NCI-H1155, we tested
the transduction efficiency of AAV2/1, AAV2/2 and
AAV2/5 (MOI of 100) in an additional 5 lung cancer cell
lines, NCI-H23, NCI-H209, NCI-H727, NCI-H510 and
NCI-H661 (Figure 1C). Due to the tropism variance that is
seen between the different lung cancer cell lines, we also
test the transduction efficiency using AAV2/4 and
AAV2/8 in the additional cell lines, NCI-H23, NCI-
H727, NCI-H510 and NCI-H661. The results indicated
that those lung cancer cells were also resistant to
AAV2/4 and AAV2/8 infection and the transduction
rate was lower than 10% (Figure 1D). NCI-H209, NCI-
H727, and NCI-H510 behaved similar to the NCI-H69
and NCI-H82 and were completely resistant to AAV in-
fection (Figure 1C, 1D). The highest infection rate seen
was with AAV2/5 in NCI-H661 at 28.7%. In the NCI-
H23 NSCLC cells, the highest infection rate was with
AAV2/1 at 21.5%. The expression of the transgene,
mCherry or EGFP could be first detected at 72-hours
post-infection with fluorescent microscopy and the sig-
nal persisted for 8 days. In all 11 lung cancer cell lines
we tested, the comparison of the transduction efficiency
of the 5 serotypes of AAV was AAV2/1 > AAV2/5 =
AAV2/2> > AAV8 > AAV4.Comparative analysis of transduction efficiency of rAAV
and VSV-G pseudotyped lentiviral vector in NCI-H69 and
NCI-H1155 cells
When infected with 5 different serotypes of AAV, NCI-
H69 and H82 were completely refractory to infection.
Less than 30% of NCI-H1155 cells were infected by
rAAV1 and only 10–15% were infected with rAAV2/2
and rAAV2/5. To seek a more efficient viral delivery
system, NCI-H69 and NCI-H1155 were infected with
lentivirus at MOI of 100. The transduction efficiency
was measured at 6 days post-infection by fluorescent
microscopy and FACS analysis (Figure 2). As previously
noted, NCI-H69 is highly resistant to infection by all the
AAV serotypes tested (Figure 1, Table 1), while the trans-
duction with the VSV-G lentivirus at the same MOI
reached 42% (Figure 2A and 2B). For NCI-H1155 cells,
AAV2/1–mediated transgene expression was 26%,
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Figure 1 Transduction efficiency of different serotypes of recombinant AAV virus in various human lung cancer cells lines. Cells were
infected with AAV2/1, AAV2/2, AAV2/4, AAV2/5 and AAV2/8 virus that carried the CMV-promoter driven mCherry transgene at a MOI 100. (A)
mCherry expression was detected by fluorescence microscopy and transduction efficiency was measured by FACS analysis (B,C,D) on day 6 post-
infection. Original magnification: 100X. The infection was done in triplicate on two separate occasions. Data are presented as the mean of
positive cells ± SEM.
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infection and the infection rate reached nearly 100%
(Figure 2C).
FACS analysis of eleven lung cancer cell lines cells with
lentivirus at increasing MOIs
Given the encouraging results seen with the NCI-H69
and NCI-H1155 cells, the panel of lung cancer cells were
tested with lentivirus. The lung cancer cells were infectedwith a serial dilution, MOI 0.04-5 of lentivirus. Most cell
lines were susceptible to lentivirus infection. At low MOI,
MOI = 5, the transduction efficiency of the lentivirus in 7
out of 11 cell lines is around 40% or higher (Figure 3). In
some of cell lines such as SHP-77, NCI-H1155, NCI-H23,
NCI-H727, and NCI-H661 even at MOI 1, the infection
rate is over 50% (Figure 3) compared to the highest trans-
duction efficiency of rAAV (MOI 100) that reached a
maximum of 40%. Even the most refractory cell lines
Table 1 Infection rates of 5 serotypes of AAV in 11 lung cancer cell lines
Cells NCI-H23 DMS53 NCI-H69 SHP77 NCI-H82 NCI-H209 NCI-H460 NCI-H510 NCI-H661 NCI-H727 NCI-H1155
Serotype
AAV2/1 24.04 ± 3.54 21.25 ± 0.12 0.27 ± 0.04 31.08 ± 0.06 0.7 ± 0.06 0.03 ± 0.001 35.6 ± 1.83 0.08 ± 0.05 24.88 ± 2.46 1.63 ± 0.15 26.05 ± 2.2
AAV2/2 12.50 ± 2.42 21.9 ± 1.44 0.3 ± 0.047 32.18 ± 1.88 0.4 ± 0.06 0.033 ± 0.001 42.6 ± 1.80 0.26 ± 0.06 17.5 ± 2.5 2.1 ± 0.2 17.93 ± 1.33
AAV2/4 6.80 ± 2.04 8.8 ± 0.42 0.4 ± 0.08 1.9 ± 0.53 0.5 ± 0.06 ND 1.5 ± 1.02 0.33 ± 0.02 6.33 ± 0.94 0.49 ± 0.07 0.5 ± 0.06
AAV2/5 9.13 ± 0.51 27.13 ± 1.34 0.3 ± 0.041 10.25 ± 1.06 1.3 ± 0.1 0.03 ± 0.001 38.5 ± 1.03 0.06 ± 0.05 28.07 ± 3.2 0.67 ± 0.15 12.13 ± 2.29
AAV2/8 10.05 ± 1.8 13.8 ± 0.15 0.4 ± 0.02 5.1 ± 0.51 0.5 ± 0.07 ND 1.2 ± 0.15 0.013 ± 0.01 6.2 ± 1.2 0.37 ± 0.13 3.3 ± 0.06































Mock AAV2/1 AAV2/2 AAV2/4 AAV2/5 AAV2/8 Lenti










































Figure 2 Comparative analysis of transduction efficiency of rAAV and lentivirus in NCI-H69 and NCI-H1155. Cells were infected with
AAV2/1, AAV2/2, AAV2/4, AAV2/5, AAV2/8 (MOI 100) and lentivirus that harbor the CMV promoter driven mCherry fluorescent protein. At 6 days
post-infection, the fluorescent signal was detected by fluorescent microscopy (A) and FACS analysis (B,C). Original magnification: 100X. (B) The
proportion of mCherry positive cells in NCI-H1155 was markedly increased for the lentivirus in comparison to all of the serotypes of rAAVs
utilized. (C) In NCI-H69, the strongest signal was observed with the lentivirus and all the rAAV virus were weaker. The infection was done in
triplicate. Data are presented as the mean of positive cells ± SEM.
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(Figure 1B and Figure 3). At MOI of 5, the transduction
efficiency of the lentivirus in NCI-H510 and NCI-H727
was 19.8% and 89.9% respectively (Figure 3). The trans-
duction efficiency of the lentivirus in the eleven lung
cancer cell lines we tested was much better than any sero-
type of AAV. The transduction rate of the lentivirus
reached or exceeded the AAV infection rates but at a
much lower MOI.
High transduction efficiency of lentivirus in the AAV-
resistant human lung cancer cell lines
At low MOI, lentivirus could reach 85–100% in the
NCI-H1155, SHP-77, NCI-H727, NCI-H661 and NCI-H23 cells. Despite this encouraging result, the H209 only
reached 5%, H510 and H69 20% and H82 30% infection
rates. Therefore, a comparison between MOI 100 of
AAV2/1, AAV2/2, and AAV2/5 (Figure 4A) was done with
a broader range of lentivirus between MOI 0.04-125
(Figure 4B). The transduction efficiency was detected
using FACS analysis on day 6 post-infection. The results
demonstrated that the transduction efficiency of the lenti-
virus was superior to all tested AAV serotypes. In contrast
to AAV, the infection rate was more than 40% in most of
the AAV-resistant cell lines except for NCI-H209 which
was resistant to all the virus types tested (Figure 4). In
NCI-H727, cells the infection rate of lentivirus reached
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Figure 4 Comparison of lentivirus transduction efficiency with AAVs in the AAV-resistant human lung cancer cell lines. NCI-H510,
NCI-H82, NCI-H69, NCI-H209 and NCI-H727 cells were infected with A) MOI 100 AAV2/1, AAV2/2 and AAV2/5 and compared to with B) lentivirus
at increasing MOI 0.04-125. Except for NCI-H209 cells, the other lung cancer cell lines that were refractory to rAAVs viral transduction were
susceptible to the lentivirus infection. The infection was done in triplicate on two separate occasions. Data are presented as the mean of
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Figure 3 The transduction efficiency of lentivirus in eleven human lung cancer lines at increasing MOIs. A lentivirus containing the CMV
promoter driven EGFP protein was infected into the human lung cancer cells at MOI 0.04-5. FACS analysis was performed on day 6. The infection
was done in triplicate on two separate occasions. Data are presented as the mean of positive cells ± SEM.
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superior to rAAV as a gene delivery system for lung cancer
gene therapy even at a low MOI.Discussion
Gene therapy is a modern and alternative treatment
for classes of cancers that cannot be readily removed
by surgery and are resistant to chemo- and radiother-
apies. Adeno-associated virus and lentivirus have been
widely studied and used for gene therapy. A high
transduction efficiency of the chosen viral delivery
vector plays an important role in the ultimate success
rate of the gene therapy [3]. AAV is rapidly becoming
one of the most popular gene delivery systems because
of its long term expression and the large number of se-
rotypes with the ability to transduce a diverse array of
cell types. Numerous serotypes of AAV have been iden-
tified and each serotype has its own unique, specific cell
tropism based on their different capsid proteins. There
are at least 10 serotypes cloned and used for packaging
the AAV2 ITR cassette to establish a recombinant AAV
with the AAV2 genome and another serotype’s capsid
protein thus expanding the cell and tissue tropism of
the AAV2 virus [6,17,18]. In the present study, we com-
pare the transduction efficiency of five different sero-
types of rAAV, AAV2/1, AAV2/2, AAV2/4, AAV2/5 and
AAV2/8 expressing the fluorescent gene mCherry or
EGFP in a variety of lung cancer cell lines. In this study,
the transduction efficiency of the AAV2/1, AAV2/5 and
AAV2/2 virus is superior to other tested serotypes. The
transduction efficiency in normal human airway epithelia
was rAAV2/1> > rAAAV2/2 = rAAV2/5 and was different
in mouse airway, rAAV2/5 > rAAV2/1> > rAAV2/2 [19].
Several studies indicated that AAV1 and AAV5 were more
efficient at transducing murine airway, human airway epi-
thelia and A549, a human adenocarcinoma lung cancer
cell line [12,19,20]. A comprehensive study of AAV1-9 se-
rotypes in isolated mouse tissues following systemic injec-
tion showed that AAV4 injection was localized to the
thoracic cavity [7]. Luciferase activity assayed from the
isolated mouse tissues showed AAV4 was highest in
heart followed by lung. Although AAV4 showed lucif-
erase activity in lung it was ten times lower than the
level in the heart. AAV4 has the highest cellular trop-
ism for muscle cells. The high AAV4 signal detected
in the chest area was most likely due to the muscle
and bone surrounding the lung [7]. Our results indi-
cated that most lung cancer cell lines are highly resist-
ant to AAV2/4 and AAV2/8. Though the transduction
profiles of rAAV serotypes are different among the lung
cancer cell lines, our result indicates that the transduc-
tion efficiency in lung cancer is rAAV2/1 > rAAV2/5 =
rAAV2/2> > rAAV2/8 > rAAV2/4.Five of the eleven lung cancer cell lines tested in this
study were resistant to all five serotypes of AAV. The
difference in lung cancer susceptibility to rAAV is most
likely due to the expression of the viral receptor on the
cell surface. The first step in AAV infection into the tar-
get cells is binding to the cell surface receptor. Five of
the lung cancer cell lines, H69, H82, H209, H510, and
H727 were completely refractory to all serotypes of AAV
infection and likely lack the cellular receptor on the cell
surface for virus binding. Unfortunately, these five lines
do not all belong to the same lung cancer subtype. NCI-
H69, H510, and H209 are classical SCLC cells, H82 are
SCLC variant, and H727 are carcinoid. Therefore, the
feasibility of using a single AAV serotype to treat even
the same class of lung cancer is not likely. The know-
ledge about the cellular receptors for the different sero-
types of AAV is not clear. Rohr et al. found that SCLC
cells were resistant to AAV2 infection because they lack
expression of the essential coreceptor FGFR-1 for viral
internalization, αV-intergrin, and heparan sulfate proteo-
glycans [8,10,21]. AAV4 and AAV5 require different
sialic acid-containing glycoproteins for binding to target
cells. The α2,3 and α2,6 sialic acid on N-linked glycopro-
teins are required for AAV5 and AAV1 binding and
transduction. The α 2,3 O-linked sialic acid glycoprotein
is required for AAV4 binding to cells [21,22]. Some
reports indicate that a 37/67-kDa laminin receptor is the
cellular receptor for AAV8 virus [23]. The different gene
sequences and the structure of the viral capsid protein
determine how it interacts with the different cellular
receptors and determine the different cell tropism for
the AAV serotypes. Future research is needed to define
the receptor of the different AAV serotypes to identify
the one most suitable for use in SCLC cells.
For the success of gene therapy for human lung
cancers, our investigation indicates that the VSV-G
pseudotyped lentivirus is superior to the AAV serotypes
investigated as a delivery system. With MOI 5, the trans-
duction efficiency of the VSV-G pseudotyped lentivirus
reached 50% in most of lung cancer cells as compared to
the highest infection rate achieved with AAV which
peaked around 30–40% at MOI 100. One report
measured the transduction rate of AAV in the lung
adenocarcinoma cell line, A549 which reached near 70%.
However, the amount of AAV particles required to
achieve this rate was MOI of 104 to 5×104. In a clinical
setting, such a high concentration of virus is not feasible.
Even at high MOI (MOI of 104), the infection rate with
AAV2/5 is less than 20% in A549 cells [20,24,25]. In
contrast, in the cells refractory to AAV infection, the
transduction rate of lentivirus at MOI 125 reached to
more than 40%. In NCI-H727 cells, the transduction
efficiency reached almost 100%. The result indicates that
the tropism of lentivirus for lung cancer cells is broad.
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not only stabilize the viral particles allowing concentra-
tion to high titers by ultracentrifugation, but also
broaden the tissue and cell tropism. The phospholipid
receptor for the VSV-G protein is expressed in a wide
variety of cells [16]. Our results show that at a low MOI,
lentivirus achieved a high infection in a variety of human
lung cancer cells. Lentivirus is the more feasible delivery
system for use in vivo or for clinical applications in lung
cancer gene therapy.
For clinical usefulness, because of the individual differ-
ences between patient tumors, we sought to define a
universal and efficient viral vector to deliver a thera-
peutic gene into multiple types of lung cancer cells.
Thus, we used eleven lung cancer cell lines to compare
the transduction efficiency of 5 serotypes of AAV with
lentivirus. Each cell line represents different classes of
lung cancer patients. Our cell line data indicates that
lentivirus has the potential for delivering a therapeutic
gene into 90% of (10/11) lung cancer patients classified
as SCLC (classical and variant), large cell carcinoma, and
carcinoid.
Conclusions
In conclusion, this study provides valuable information
on choosing an effective viral delivery system for future
gene therapy studies targeting human lung cancer cells.
The ability of the lentivirus to readily infect a human
lung cancer cell is due to the VSV glycoprotein. There-
fore, the use of lentivirus armed with a therapeutic gene
would be the optimal choice for delivery into various
types of human lung cancer as an alternative treatment
option.
Materials and methods
Production of different serotypes of rAAV
The AAV vector plasmid, pAAV2-EGFP (Agilent Tech-
nologies) harbors a CMV driven- enhanced GFP gene
expression cassette flanked by inverted terminal repeats
(ITRs). pAAV-RC plasmid harbors the AAV2 rep and
cap genes encoding the replication and virus capsid
structural protein. The pHelper plasmid contains the
essential subset of adenovirus genes, VA, E2A and E4
necessary for AAV production in the AAV-293 cells
(Agilent Technologies). For AAV2/2 production, the
three AAV plasmids (10 ug of each plasmid) were co-
transfected into AAV-293 cells using the CalPhos
Mammalian transfection kit (Clontech, Mountain View,
CA). For AAV2/1 and AAV2/5 production, two plasmids
were used, pAAV2-EGFP and the pDP1rs or pDP5rs
(Aldevron Fargo, North Dakota) which contains AAV2
rep and AAV1 cap gene or AAV5 cap gene and a subset
of adenovirus genes, VA, E2A and E4 necessary for AAV
production in AAV-293 cells. AAV-293 cells weretransfected with the two plasmids at a ratio of 3:1
pAAV2-EGFP and pDP using the CalPhos Mammalian
transfection kit to produce the AAV2/1 or AAV2/5
vectors. The medium was removed and replaced with
15 ml of fresh medium 6 hours after transfection and
the plates returned to the 37°C incubator for an ad-
ditional 72 hours. The transfected cells and the culture
medium were transferred into 50-mL conical tubes and
the cells were spun down at 500×G for 10 min at 4°C.
The supernatant was discarded and the cell pellets were
resuspended in 1X PBS buffer. The cell suspension was
subjected to 4 rounds of freeze/thaw lysis by switching
the tubes between a dry ice-ethanol bath and a 37°C
water bath. The cell debris was removed by centrifuga-
tion at 1000×G for 10 minutes and then the supernatant
was collected. The supernatant containing the crude
viral particles were pelleted by high speed centrifugation
at 100,000×g for 16 hr at 4°C. Following centrifugation,
the pellet was resuspended by vigorous agitation in 5 ml
of DNase buffer (10 mM Tris.Cl, pH7.5, 10 mM MgCl2)
followed by addition of 1,000 units of DNase I and incuba-
tion for 1 hr at 37°C. To inactivate the DNase I, 250 μL of
0.5 M EDTA was added and the debris was removed by
centrifugation at 10,000×g for 2 min. The supernatant was
loaded onto a two-tier CsCl gradient (1.25 g/ml and
1.50 g/ml) and spun at 35,000 rpm for 2 h at 16°C in an
SW40 rotor (Beckman Instruments, Palo Alto, CA). The
band that contained the viral particles was collected and dia-
lyzed in a Slide-A-Lyzer cassette (Pierce, Rockford, IL) to de-
salt the virus fraction with PBS buffer. The supernatant was
harvested and contained the desalted virus particles. The
AAV viruses were stored at −80°C. All AAV and lentivirus
production was done in accordance with Institutional Bio-
safety Committee (IBC) approval from the Research Insti-
tute for Children at Children's Hospital, New Orleans, LA.
The AAV2/1, AAV2/4, AAV2/5, and AAV2/8 viral
vectors carrying the CMV promoter-driven mCherry
transgene were obtained from the Gene Transfer Vector
Core Lab, University of Iowa (Iowa City, IA).
Production of lentivirus
Lentiviral particles pseudotyped with the VSV-G glyco-
protein were generated by calcium phosphate-mediated
transfection of 293FT cells. 293 FT cells were seeded in
150-cm2 plates. Twenty four hours later, the medium
was removed and the fresh medium with 25 uM chloro-
quine (Sigma-Aldrich) was added. The lentiviral vector,
packaging, and envelope glycoprotein plasmids were
transfected into 293FT cells with the CalPhos Mammalian
transfection kit (Clontech, Mountain View, CA) according
to the manufacturer’s instruction. The amount of DNA
used per plate was 20 μg of lentiviral vector plasmids
pNL-CMV/EGFP/WPREΔU3 or pNL-CMV/mCherry/
WPRE ΔU3, 13 μg of packaging plasmid pCD/NL-
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gift from Jakob Reiser, FDA, Silver Spring, MD. The
medium was removed 12 hr after transfection and
replaced with 15 ml of fresh culture medium. Forty eight
hours post transfection, the vector-containing medium
was harvested. The harvested medium was centrifuged at
500 × g for 5 min and filtered through a 0.45-μ pore size
filter (Pall Co., Ann Arbor, MI) to remove the cell debris.
For vector concentration by ultracentrifugation, the
filtered vector-containing medium was transferred into
high speed centrifuge tubes (Beckman Coulter, Fullerton,
CA) and centrifuged for 2 h at 25,000 rpm at 4°C using a
Beckman SW32Ti ultracentrifuge rotor (Beckman Coulter,
Fullerton, CA). The resulting pellet was resuspended in
100 μl of PBS for 2 h at 4°C. Virus aliquots were stored
at −80°C.Viral titer measurement
For the lentivirus, the viral titers were determined by
using flow cytometry analysis (BD Biosciences). Hela
cells were infected with a serial dilution from 100 to 105
of the lentivirus containing CMV promoter driven fluor-
escent gene mCherry or EGFP in Dulbecco’s modified
Eagle’s medium with 8 ug/mL polybrene (Sigma-Aldrich,
Milwaukee, WI). Twenty four hours post-infection, the
medium was removed and replaced with fresh medium
without polybrene. Forty eight hours later, the supernatant
was discarded and the Hela cells were harvested. The cells
were fixed with 4% paraformaldehyde buffer and the pro-
portion of infected cells was detected by flow cytometry
analysis to determine the titer.
For AAV virus, the viral titer was measured using
HT-1080 cells. A serial dilution of the AAV virus was
added to the HT1080 cells. After 2 hours, fresh medium
was added to the cells and then incubated at 37°C for an
additional 48 hours. The proportion of AAV infected
cells were determined by flow cytometry analysis.Cell lines and culture
The cells used for virus production, 293FT cells (Life
Technologies) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM, high-glucose) supplemented with
10% FBS, 1% Glutamine, 1 mM sodium pyruvate, 0.1 mM
non-essential amino acids, 1X Pen/Strep (10,000 IU peni-
cillin and 10,000 ug/ml streptomycin), with 500 ug/mL
geneticin (Mediatech, Inc., Manassas, VA). AAV-293,
HT1080 (Agilent Technologies, La Jolla, CA) and Hela
cells (ATCC) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, high-glucose) with 10% fetal calf serum
(Atlanta Biological Inc., Norcross, Georgia), 1X Pen/Strep
(10,000 IU penicillin and 10,000 ug/ml streptomycin)
(Mediatech, Inc., Manassas, VA.) in a 5% CO2 incubator
at 37°C.The human SCLC cell lines, DMS 53, NCI-H69, NCI-
H82, NCI-H209, NCI-H510 and SHP-77, as well as
NSCLC cell lines, NCI-H23 (adenocarcinoma), NCI-H661,
NCI-H460 and NCI-H1155 (large cell lung cancer), NCI-
H727 (carcinoid) were obtained from the American Type
Culture Collection, Manassas, VA and cultured in RPMI
1640 medium (Mediatech, Inc., Manassas, VA.)
supplemented with 10% fetal calf serum (Atlanta Biological
Inc., Norcross, Georgia), 1X Pen/Strep (Mediatech, Inc.,
Manassas, VA.) in a 5% CO2 incubator at 37°C.
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